Table 2.
Univariable association of demographic and clinical characteristics with staging MRI
| Independent variable | Characteristic | OR (95% CI) | P value |
|---|---|---|---|
| Age (y) | 0.92 (0.89-0.94) | <.001 | |
| Race | Black vs white | 0.51 (0.35-0.73) | <.001 |
| Other vs white | 1.40 (0.61-3.23) | .432 | |
| Poverty | Yes vs no | 0.53 (0.36-0.77) | <.001 |
| Distance (miles) | ≥45 vs <45 | 1.79 (1.11- 2.88) | .017 |
| Primary insurance | Nonprivate vs private | 0.57 (0.39-0.84) | .005 |
| Treatment Year | 2008-2009 vs 2005-2007 | 0.43 (−0.05 to 2.63) | .076 |
| 2010-2013 vs 2005-2007 | 1.40 (0.61-3.23) | .432 | |
| PSA (ng/mL) | 0.99 (0.98-1.01) | .354 | |
| Gleason score | 7 vs 6 | 0.96 (0.66-1.41) | .845 |
| 8 vs 6 | 0.87 (0.44-1.72) | .683 | |
| 9 vs 6 | 0.56 (0.27-1.15) | .112 | |
| Clinical T stage | T2 vs T1 | 0.81 (0.53-1.24) | .337 |
| T3 vs T1 | 3.37 (1.42-7.97) | .006 | |
| Risk group | Intermediate vs high | 1.27 (0.81-2.00) | .296 |
| Low vs high | 1.17 (0.73-1.86) | .514 | |
| Percent positive biopsy cores | 0.64 (0.25-1.63) | .348 | |
| IPSS | 0.99 (0.95-1.03) | .589 |
CI, confidence interval; IPSS, International Prostate Symptom Score; MRI, magnetic resonance imaging; OR, odds ratio; PSA, prostate-specific antigen.